Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 08:15PM GMT
Release Date Price: $48.12 (-1.33%)
David Reed Risinger;Giovanni
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

Thanks for joining this next session with Bristol-Myers. I need to first refer you to disclaimers at www.morganstanley.com/researchdisclosures. It's very much my pleasure to welcome the Chairman and CEO of Bristol-Myers, Giovanni Caforio. For those of you who don't know, he originally joined Bristol-Myers back in 2000. He started his career as a physician originally but joined Bristol in 2000 as VP and General Manager in Italy. And he took on positions of increasing responsibility, eventually becoming Chief Commercial Officer in 2013, Chief Operating Officer in 2014 and CEO in 2015. And before his time at Bristol-Myers, he spent 12 years with Abbott. So we're very much fortunate to have Giovanni with here -- with us here today.

I thought it would be helpful just to maybe turn it over to you to provide a couple of opening remarks, and then we'll go from there.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot